microdose glp 1 for inflammation Thinking About Microdosing GLP-1? 5 Myths Debunked | Live Healthy Antiinflammatory actions of glucagon-like peptide-1–based

Molecular Cloning and Sequence Analysis of a Calcium-Activated Neutral Protease (Calpain) From Schistosoma Mansoni

Companies like Lifelabs and Dynacare offer comprehensive panels at reasonable costs across most Canadian provinces

Ensures durable weight management with measurable, sustainable results years after surgery

To view or add a comment, sign in Samjin Pharmaceutical applies for domestic Phase 1 clinical trials of novel inflammation and immunology drug candidate SJN314 Samjin Pharmaceutical (hereinafter referred to as Samjin Pharm) announced on February 4 that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for a Phase 1 clinical trial of SJN314 (development code). The candidate represents a key asset within the company's novel drug research pipeline focused on Inflammation & Immunology. SJN314 is an orally administered, small-molecule inhibitor of Mas-related G-protein-coupled receptor X2 (MRGPRX2), being developed for the treatment of inflammatory conditions such as chronic spontaneous urticaria (CSUR) and atopic dermatitis